Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Int Immunopharmacol ; 123: 110577, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37567010

ABSTRACT

BACKGROUND: Immunosuppression is an integral part of treating chronic spontaneous urticaria (CSU), but there is no literature to evaluate the efficacy of multiple immunosuppressive agents. OBJECTIVE: The comparison of the efficacy, safety, and incidence of adverse effects of four immunosuppressive medicines (tripterygium glycosides, methotrexate, cyclosporine A, and azathioprine) in combination with antihistamines in treating CSU provides a clinical reference and evidence-based medicine for treating CSU. METHODS: PUBMED, The Cochrane Library, EMBASE, WANFANG, CNKI, CBM, and clinical trial registration platform were searched to collect relevant randomized controlled trials (RCT) and cohort studies of four immunosuppressive medicines combined with antihistamines for treating CSU. The primary outcomes were the efficacy of weekly urticaria activity score 7 (UAS7) and adverse effects. RESULTS: This study pooled data from seven randomized clinical trials with 410 participants. The standardized mean differences for change in UAS7 were 0.10 (95% confidence interval (CI), 0.01 to 0.68) for cyclosporine A plus antihistamine; 0.03 (95% CI, 0.00 to 0.23) for azathioprine plus antihistamine; 0.52 (95% CI, 0.32 to 0.85) for tripterygium glycosides plus antihistamine; and 1.54 (95% CI, 0.64 to 3.67) for methotrexate plus antihistamine. There were no significant differences in side effects between these medicines in the limited number of trials and clinical samples. CONCLUSION: Our results indicate that cyclosporine A combined with antihistamine resulted in greater improvements regarding the UAS7 in CSU patients and that tripterygium glycosides are also effective in treating CSU.


Subject(s)
Anti-Allergic Agents , Chronic Urticaria , Drug-Related Side Effects and Adverse Reactions , Urticaria , Humans , Immunosuppressive Agents/therapeutic use , Cyclosporine/therapeutic use , Methotrexate/therapeutic use , Azathioprine/therapeutic use , Network Meta-Analysis , Chronic Disease , Chronic Urticaria/chemically induced , Chronic Urticaria/drug therapy , Histamine H1 Antagonists/therapeutic use , Urticaria/drug therapy , Histamine Antagonists , Drug-Related Side Effects and Adverse Reactions/drug therapy , Glycosides/therapeutic use , Treatment Outcome , Omalizumab/therapeutic use , Anti-Allergic Agents/therapeutic use , Randomized Controlled Trials as Topic
2.
Chinese Journal of Immunology ; (12): 31-35, 2017.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-508451

ABSTRACT

Objective:To study the immunological characteristics of recombinant Rv3425 protein,to evaluate its diagnosis value and the role in the pathogenicity. Methods: Rv3425 gene was cloned into pET28a vector,the recombinant protein was induced and purified;we analyzed the antigenicity and specificity of Rv3425 by ELISA ( Enzyme-linked immuno sorbent assay) and Western blot methods,apoptosis effect of Rv3425 to macrophage was deteced by FCM ( Flow cytometry method ) . Results: Purified prokaryotic expressed protein Rv3425 was acquired,we found Rv3425 could elicit high level of IFN-γin spleen cells and combine with the serum of iH37Rv (inactivated mycobacterium tuberculosis) immunized mice;the specific IgG and IgM antibodies of TB (Tuberculosis) patients were significantly higher than healthy donors;Rv3425 also could induce the necrosis of macrophage. Conclusion:Our study found that Rv3425 had strong antigenicity and could induce the apoptosis of macrophage,these findings were very important for the research of TB diagnosis and pathogenicity.

SELECTION OF CITATIONS
SEARCH DETAIL
...